A well-timed news release with the BIO CEO & Investor Conference happening today and tomorrow. RVX and Zenith both present tomorrow.

Here is the article on the photoreceptor protection:

Photoreceptor protection via blockade of BET epigenetic readers in a murine model of inherited retinal degeneration.

Importantly, they show that the major phenotypes of activated microglia (inflammation, proliferation, and migration) are blocked by the bromodomain-2 selective BET inhibitor (RVX-208), whereas the bromodomain-1 selective BET inhibitor (Olinone) was much less effective. So once again, we see the advantage of Resverlogix having the only bromodomain-2 selective BET inhibitor in clinical trials. Also, please note that this photoreceptor protection study was done at University of Wisconsin-Madison (Go Badgers!).